pharmaceutics

MDPI

Correction

Correction: Donthi et al. Dasatinib-Loaded Topical Nano-Emulgel for Rheumatoid Arthritis: Formulation Design and Optimization by QbD, In Vitro, Ex Vivo, and In Vivo Evaluation. *Pharmaceutics* 2023, *15*, 736

Mahipal Reddy Donthi, Ranendra Narayan Saha *, Gautam Singhvi and Sunil Kumar Dubey *,†

Department of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Pilani 333031, Rajasthan, India; p20190054@pilani.bits-pilani.ac.in (M.R.D.); gautam.singhvi@pilani.bits-pilani.ac.in (G.S.)

* Correspondence: rnsaha.bits@gmail.com (R.N.S.); sunilbit2014@gmail.com (S.K.D.); Tel.: +91-94140826 (R.N.S.); +91-8239703734 (S.K.D.)

† Present address: R&D Healthcare Division Emami Ltd., 13, BT Road, Belgharia, Kolkata 700056, West Bengal, India.

Error in Figure

In the original publication [1], there was a mistake in Figure 11 as published. In this study, the 72-h time point is considered after treatment. To maintain transparency, we included images from several time points which led to inadvertent duplication during the image combining process. Specifically, in each cohort, the 0-h time point includes two images (pre- and post-formulation), and for Group I (negative control, zero hour), no formulation was applied, hence the images look similar. Additionally, we noticed a similarity between the 24-h image of Group II and that of Group III, likely due to our error in arranging the images. However, as detailed in Section 3.16.1 of the manuscript, our conclusions are based on histopathological results at the 72-h mark, with earlier time points serving only for preliminary visual inspection. The corrected Figure 11 appears below.




Figure 11. In vivo skin irritation study of Group I—untreated group; Group II—FDG (200 mg from 0.05% gel); Group III—CF018 emulgel (200 mg from 0.05% gel); Group IV—CF018P emulgel (200 mg from 0.05% gel); Group V—received 5% SLS gel.

Received: 26 March 2025
Accepted: 31 March 2025
Published: 16 April 2025

Citation: Donthi, M.R.; Saha, R.N.; Singhvi, G.; Dubey, S.K. Correction: Donthi et al. Dasatinib-Loaded Topical Nano-Emulgel for Rheumatoid Arthritis: Formulation Design and Optimization by QbD, In Vitro, Ex Vivo, and In Vivo Evaluation. *Pharmaceutics* **2023**, *15*, 736. *Pharmaceutics* **2025**, *17*, 525. https://doi.org/10.3390/pharmaceutics17040525

Copyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

1. Donthi, M.R.; Saha, R.N.; Singhvi, G.; Dubey, S.K. Dasatinib-Loaded Topical Nano-Emulgel for Rheumatoid Arthritis: Formulation Design and Optimization by QbD, In Vitro, Ex Vivo, and In Vivo Evaluation. *Pharmaceutics* **2023**, *15*, 736. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.